STTK, US82024L1035

UBS upgrades Shattuck Labs stock to strong buy at USD 17 target

Published on 10/16/2026 at 02:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS set a USD 17.00 target on October 12, 2026. Shattuck Labs stock stood at a USD 550.98 million market value below a USD 8.33 high.

Research signals and clinical milestones

UBS upgraded Shattuck Labs to strong buy on October 14, 2026.
The company reported a USD 15.15 million net loss for the second quarter of 2026.
Shattuck Labs had a USD 550.98 million market capitalization on October 14, 2026.

STTK, US82024L1035, Illustration mit AI erstellt.

Shattuck Labs (ISIN US82024L1035) was upgraded to strong buy by UBS on October 14, 2026, as analysts continued to value the biotechnology company's SL-325 program. MarketBeat reported that the upgrade joined strong-buy ratings from TD Cowen and Raymond James.

Analysts raise the valuation bar

Investing.com reported on October 12, 2026, that UBS began coverage with a buy rating and a USD 17.00 price target. The firm also estimated adjusted 2035 sales of USD 2.90 billion for SL-325, compared with a USD 1.20 billion consensus estimate.

The analyst range widened earlier in October. Markets Insider reported on October 2, 2026, that Needham raised its target from USD 17.00 to USD 19.00 while maintaining a Buy rating.

Three dated valuation signals

On October 2, 2026, Needham set the USD 19.00 target after Shattuck expanded SL-325 development into hidradenitis suppurativa, according to Markets Insider. On October 12, 2026, UBS initiated coverage at USD 17.00, as reported by Investing.com. On October 14, 2026, MarketBeat cited a USD 13.70 consensus target and the UBS upgrade.

What does USD 17.00 mean?

The UBS target sits above the USD 13.70 consensus cited by MarketBeat on October 14, 2026, but the target comparison remains dependent on clinical execution. The company reported a net loss of USD 15.15 million and basic earnings per share of negative USD 0.12 for the second quarter of 2026, according to MarketBeat. The investor-relations page lists the second-quarter 2026 Form 10-Q among the company's latest financial results.

Clinical program remains central

Shattuck describes SL-325 as a DR3 antagonist antibody designed to block the TL1A/DR3 pathway in inflammatory bowel disease and other immune-mediated diseases, according to its investor-relations overview. The company also plans to evaluate the candidate in a Phase 2 hidradenitis suppurativa study, a development cited in the October analyst reports.

Market value and risk profile

MarketBeat placed Shattuck Labs at a USD 550.98 million market capitalization on October 14, 2026, with a 52-week range of USD 1.70 to USD 8.33. That valuation gives the analyst targets a clear numerical frame, while the second-quarter loss shows why clinical milestones remain the central risk factor for the biotechnology story.